VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, today announced a project with Merck Research ...

Vancouver firm's AI platform will generate chemical compounds based on Merck’s therapeutic targets. A Vancouver startup using artificial intelligence (AI) to discover new drugs has struck a deal with ...

Variational AI CEO Handol Kim's company has a platform that uses the language of chemistry to create drug recipes | Rob Kruyt Multinational drug developer Merck is partnering with a Vancouver-based ...

Generating synthetic data is useful when you have imbalanced training data for a particular class, for example, generating synthetic females in a dataset of employees that has many males but few ...

Merck & Co. is taking a look at a generative AI platform. As an early user of Variational AI’s technology, the Big Pharma will assess the ability of the platform to generate novel small molecules that ...

MSD has signed an agreement with Variational AI to use its generative AI (genAI) platform Enki in the discovery of new small-molecule medicines. Vancouver, Canada-based Variational – which emerged in ...